Humacyte, Inc. (HUMA) Stock Sinks As Market Gains: Here's Why
The latest trading day saw Humacyte, Inc. (HUMA) settling at $0.78, representing a -2.32% change from its previous close.
HUMA - Humacyte, Inc.
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$5.58
DETAILS
HIGH:
$10.00
LOW:
$3.00
MEDIAN:
$5.50
CONSENSUS:
$5.58
UPSIDE:
704.38%
Stock News
Here's Why Humacyte, Inc. (HUMA) Fell More Than Broader Market
Humacyte, Inc. (HUMA) concluded the recent trading session at $0.62, signifying a -11.14% move from its prior day's close.
Brokers Suggest Investing in Humacyte, Inc. (HUMA): Read This Before Placing a Bet
When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?
Humacyte, Inc. (HUMA) Dips More Than Broader Market: What You Should Know
Humacyte, Inc. (HUMA) closed the most recent trading day at $1.03, moving 3.74% from the previous trading session.
Humacyte, Inc. (HUMA) Discusses V012 Study Top-Line Results for Engineered Vessel in Dialysis Access Transcript
Humacyte, Inc. (HUMA) Discusses V012 Study Top-Line Results for Engineered Vessel in Dialysis Access Transcript
Humacyte, Inc. (HUMA) Upgraded to Buy: Here's What You Should Know
Humacyte, Inc. (HUMA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Humacyte's Bioengineered Blood Vessel Outperforms the Standard of Care for Women on Dialysis in Phase 3 Results Presented at the Society for Vascular Surgery Vascular Annual Meeting
– Positive results from the V012 Phase 3 study were presented at the Society for Vascular Surgery's Vascular Annual Meeting in Boston – – Women who received Humacyte's ATEV experienced an average of three more months without a dialysis catheter than women who received AV fistula, the current standard of care – – Company to hold investor event today, June 15 th , at 5:00 p.m. ET – DURHAM, N.C.
Humacyte, Inc. Announces Pricing of Public Offering of Common Stock
DURHAM, N.C., June 10, 2026 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today announced the pricing of an underwritten public offering of 47,619,048 shares of its common stock at a public offering price of $1.05 per share. The aggregate gross proceeds from this offering are expected to be $50 million, before deducting underwriting discounts and commissions and other offering expenses payable by Humacyte. The closing of the offering is expected to occur on or about June 12, 2026, subject to the satisfaction of customary closing conditions. In addition, Humacyte has granted the underwriters an option for a period of 30 days to purchase up to an additional 7,142,857 shares of Humacyte's common stock at the public offering price, less underwriting discounts and commissions. All of the shares of common stock are being sold by Humacyte.
Humacyte, Inc. Announces Proposed Public Offering of Common Stock
DURHAM, N.C., June 10, 2026 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today announced that it has commenced an underwritten public offering of its common stock. In addition, Humacyte intends to grant the underwriters an option for a period of 30 days to purchase up to an additional 15% of the number of shares of common stock sold in connection with the offering. All of the shares of common stock are being offered by Humacyte.
Humacyte ATEV Met Superiority Primary Endpoint Compared to Standard of Care AV Fistula in Interim Analysis of V012 Phase 3 Study in Female Dialysis Access Patients
- Humacyte plans to file a supplemental Biologic License Application (BLA) with the Food and Drug Administration (FDA) during the second half of 2026 -
Humacyte ATEV Met Superiority Primary Endpoint Compared to Standard of Care AV Fistula in Interim Analysis of V012 Phase 3 Study in Female Dialysis Access Patients
- Humacyte plans to file a supplemental Biologic License Application (BLA) with the Food and Drug Administration (FDA) during the second half of 2026 - - The ATEV met V012's primary endpoint and was observed to have superior catheter-free days (p=0. 00070) compared to autologous arteriovenous (AV) fistula, the current standard of care - - The ATEV's ability to reduce time on catheter has the potential to improve patient outcomes and lower the burden of dialysis costs on the healthcare system.
Did Humacyte, Inc. Insiders Breach their Fiduciary Duties to Shareholders?
Did Humacyte, Inc. Insiders Breach their Fiduciary Duties to Shareholders? PR Newswire NEW YORK, June 5, 2026
Did Humacyte, Inc. Insiders Breach their Fiduciary Duties to Shareholders?
Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible for out-of-pocket payment of our legal fees or expenses.
Wall Street Bulls Look Optimistic About Humacyte, Inc. (HUMA): Should You Buy?
When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?
Humacyte Announces Presentation at VASA Meeting of Research Highlighting Self-Repair of ATEV After Cannulation for Dialysis Access
- Dialysis access requires frequent cannulation, often exceeding 300 needle punctures annually - - The ATEV was observed to maintain long-term structural integrity and self-repair with smooth muscle cell repopulation despite repeated cannulations - - Humacyte anticipates that top-line interim results from its ongoing V012 Phase 3 study in dialysis access will be available for reporting in June - DURHAM, N.C., May 26, 2026 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today announced the presentation of research providing evidence of self-repair of the acellular tissue engineered vessel (ATEV) after cannulation for dialysis access at the Vascular Access Society of the Americas (VASA) 2026 Vascular Access for Dialysis Symposium in Salt Lake City, Utah.
Humacyte Announces Symvess® is Now Under Contract with the Strategic Acquisition Center (SAC) of the U.S. Department of Veterans Affairs
- Surgical Implant – Next Generation contract makes Symvess more easily accessible to 170 VA hospitals – - SAC awards require intensive product and value analysis vetting by a surgical committee and streamline the approval process by individual hospitals - DURHAM, N.C., May 20, 2026 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissue at commercial scale, announced today that Symvess is now under contract with the with Strategic Acquisition Center (SAC) of the U.S. Department of Veterans Affairs (VA).
Humacyte Q1 Earnings Call Highlights
Humacyte NASDAQ: HUMA reported first-quarter 2026 Symvess sales of $0.5 million and outlined a series of commercial, clinical and cost-reduction initiatives aimed at accelerating adoption of its bioengineered vascular products.
Humacyte, Inc. (HUMA) Reports Q1 Loss, Misses Revenue Estimates
Humacyte, Inc. (HUMA) came out with a quarterly loss of $0.09 per share versus the Zacks Consensus Estimate of a loss of $0.1. This compares to a loss of $0.1 per share a year ago.
Humacyte Announces First Quarter 2026 Financial Results and Provides Business Update
- Appointed Jim Mercadante as Chief Commercial Officer and Dr. Todd Rasmussen as Chief Surgical Officer - - First quarter sales of Symvess® were $0.5 million in 2026 compared to $0.1 million in 2025 - - Purchase commitment received for a minimum of $1.475 million for a clinical evaluation and outreach program in the Kingdom of Saudi Arabia - - Announced Israeli Ministry of Health Acceptance of Marketing Authorization Application for Symvess for Vascular Injury Repair - - U.S. Department of Defense funding for procurement of bioengineered blood vessels - - Major milestone upcoming: Top-line interim results from V012 Phase 3 study in hemodialysis access - -Conference call today at 8:00 am ET - DURHAM, N.C., May 13, 2026 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today announced financial results for the first quarter ended March 31, 2026, and provided a business update.
Humacyte Appoints Dr. Todd E. Rasmussen as Chief Surgical Officer
- Distinguished vascular surgeon brings decades of clinical experience, innovation, and leadership to new role at cutting-edge biotech manufacturer -
Price Targets
H.C. Wainwright Reiterates Buy Rating on Humacyte (HUMA)
$3.00
(was $1.35)
Swayampakula Ramakanth
·
H.C. Wainwright
Humacyte price target lowered to $6 from $7 at BTIG
$6.00
(was $1.68)
UBS
Humacyte initiated with an Overweight at Barclays
$3.50
(was $1.47)
Matt Miksic
·
Barclays
Piper Sandler Reiterates Neutral Rating on Humacyte (HUMA)
$6.00
(was $4.86)
Matt O'Brien
·
Piper Sandler
BTIG Reiterates Buy Rating on Humacyte (HUMA)
$10.00
(was $4.86)
Ryan Zimmerman
·
BTIG
Humacyte (HUMA) Stock Gets A $5 Price Target
$5.00
(was $2.21)
Cowen Cowen
·
Cowen & Co.
Humacyte downgraded to Underweight from Overweight at Piper Sandler
$4.00
(was $5.37)
Matt O'Brien
·
Piper Sandler